ArticleAmerican journal of translational research2025
Mosapride combined with rebamipide demonstrates superior efficacy for treatment of chronic atrophic gastritis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the therapeutic efficacy of combining mosapride with rebamipide for treatment of chronic atrophic gastritis (CAG).
methodsA total of 116 patients with confirmed CAG were enrolled. The control group (n=52) received mosapride alone, while the observation group (n=64) was treated with both mosapride and rebamipide. Therapeutic outcomes, adverse events, pathological scores, symptom relief time, and serological markers were compared between the groups. Univariate and multivariate analyses were also conducted to identify factors influencing treatment efficacy.
resultsThe observation group exhibited a significantly higher overall effective rate than the control group (P<0.05), with no significant difference in adverse events (P>0.05). Pathological scores were significantly lower in the observation group both compared to baseline and to the control group (P<0.05). Additionally, the observation group had greater improvements in all serological markers and a shorter duration to symptom relief (all P<0.05). Multivariate analysis identified smoking history (P=0.017, OR=4.318), alcohol consumption history (P=0.002, OR=6.327), and epidermal growth factor levels (P=0.044, OR=3.394) as independent risk factors for treatment response.
conclusionThe combination of mosapride and rebamipide offers superior efficacy in managing CAG without increasing adverse effects. It significantly improves pathological conditions, expedites symptom resolution, and enhances gastric mucosal biomarker profiles, supporting its broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.